Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

autoimmune disease

- PMLiVE

Sanofi/GSK’s next-generation COVID-19 booster granted EC approval

Two trials compared the immune response induced by VidPrevtyn Beta with approved vaccines

- PMLiVE

AstraZeneca/Sanofi’s Beyfortus receives EC approval for prevention of RSV in infants

The decision makes the antibody the first broadly protective option for this age population

How Pharma, Payers, & Providers are Leveraging Patient Self-Management Platforms

Rick Anderson, President of DarioHealth, explores digital therapeutics, how DarioHealth is utilizing AI and behavioral science to personalize each user’s health journey, and how this approach can help improve diversity...

Impetus Digital

- PMLiVE

Verge Genomics begins human trials with AI-sourced ALS drug

VRG50635 was discovered by the company’s all-in-human, AI-powered platform

- PMLiVE

QiC Diabetes awards 2022 celebrate UK healthcare excellence

The annual awards recognise the efforts of NHS teams and individuals

- PMLiVE

How to elevate your communications testing with AI powered insights and analytics

Learn about a new behavioural science-led framework incorporating AI technologies that ensures you get a true reflection of how your communications materials are consumed and processed by customers

Research Partnership

- PMLiVE

New study links genetic traits of Black Death survivors and autoimmune diseases today

The study involved the extraction and screening of more than 500 ancient DNA samples

- PMLiVE

Amgen completes acquisition of ChemoCentryx in deal worth $3.7bn

Amgen gains access to the biopharma’s autoimmune disease treatment Tavneos

- PMLiVE

WHO unveils AI-powered digital health worker, Florence 2.0

The chatbot builds on its previous version, which was used to tackle COVID-19 misinformation

- PMLiVE

Brainomix set to collaborate with NCIMI to assess AI-powered tech in lung cancer care

The partnership will compare automated evaluation versus observations of medical specialists

- PMLiVE

Incyte to acquire Villaris Therapeutics to expand inflammation and autoimmunity portfolio

Auremolimab, which has proven efficacy for vitiligo, is included in the deal

- PMLiVE

Sanofi and Regeneron’s Dupixent approved by FDA for prurigo nodularis

The two phase 3 trials showed a meaningful reduction in itching

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links